We Fuel a Network of Leaders that Drive Virginia Bioscience
We are made up of the people who do the research, development and commercialization of biosciences in Virginia, and the suppliers, consultants, attorneys, accountants and others who work to support the industry.
Our Sponsors
Driven by Innovation & Growth
Our mission is to promote innovation and growth through strengthened networks; advocacy; capital investment; talent attraction, development and retention; and advancing the next generation of leaders.
Virginia's Life Science Community By the Numbers
-
1,451 Companies
Life science companies in Virginia.
-
$8B Industry
Life Science contributes $8B to Virginia's economy.
-
26,545 People
Employed by Life Science companies in Virginia.
-
$77,848 Average Wage
Average earnings of life science workers in Virginia.
-
1,197 Clinical trials
Biopharmaceutical industry-sponsored trials in Virginia per year.
Upcoming Events
avantor delivered by vwr: Session 2 – Introduction to Bioprocessing Single Use & Controlled Environment
07/21/2022
11:00 am – 11:30 am EST
avantor delivered by vwr: Session 3 – Chromatography & Analytical Chemistry Portfolios
08/18/2022
11:00 am – 11:30 am EST
News
06/29/2022
Bio-plastics startup wins Lighthouse Labs pitch contest
Charlottsville, VA (Virginia Business) – While pitching to the sharks, entrepreneur Alec Brewer told them, “I do have white powder in my pocket,” before quickly clarifying that it wasn’t an illicit substance: “It’s PHB! It’s PHB!” The co-founder and CEO of Charlottesville-based biodegradable plastics manufacturer Ourobio, Brewer explained that his company makes PHB, or polyhydroxybutyrate, …
06/26/2022
USA FDA Grants Fast Track Designation to ReAlta Life Sciences’ Lead Compound RLS-0071
ReAlta Life Sciences (“ReAlta”), Inc., a clinical stage, rare disease company dedicated to harnessing the power of the immune system to address life threatening diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to RLS-0071 for the treatment of hypoxic ischemic encephalopathy (HIE). RLS-0071 is the Company’s lead dual …
06/20/2022
Adial Pharmaceuticals Awarded Additional U.S. Patent Combining the Use of the Company’s Proprietary Genetic Diagnostic With AD04 to Treat Alcohol and Drug Dependence
New patent covers the use of the full genetic panel measuring all five genetic biomarkers CHARLOTTESVILLE, Va., — Adial Pharmaceuticals, Inc. (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 11,351,154 was issued on June 7, 2022, by …
Our Premium Partners
